cnn tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says Tirzepatide Side Effects: How Zepbound

The expression and distribution of FFARs such as GPR40, GPR119, and GPR120 in L and cells and glucose, along with their dual effects on insulin and GLP-1 secretion, have made them attractive therapeutic targets, leading to the development of agonists for these receptors for the treatment of T2DM [150,151,152,153,154]

Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E, Investigators P

By mimicking a hormone called GLP-1, which is naturally produced in the gut after eating, it helps lower blood sugar, reduce sugar production in the liver, and control calorie intake

Full clinical and market details here: Preapared by HEALTHCARE ALLIANCE VIETNAM #GLP1 #ObesityTreatment #WeightLossTherapy #Pharma #NovoNordisk #HealthcareInnovation #Cardiometabolic #Biopharma #HealthcareAlliance #HealthcareInsights To view or add a comment, sign in Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US.3 Wegovy pill is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.3 Wegovy pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease

It slows down gastric emptying

The oral version is priced between $289 and $249 per month, with potential savings of up to $600 annually